UN High-Level Meeting on TB Roundup

The first ever U.N. General Assembly’s high-level meeting (UNHLM) on tuberculosis took place on Wednesday, September 26 in New York City. The U.N. delegation of countries agreed to ambitious targets including a commitment to finding 40 million undiagnosed cases of TB by the end of 2022 and increasing annual investment in TB to $13 billion by then, too.  Endorsement of the political declaration on TB is not enough; we need to see countries bringing these commitments into action including closing the $1.3 billion annual funding gap for TB research and product development. 

Some countries led the charge including the UK government, who announced at the meeting that they have committed to invest in the development of shorter, safer and more effective treatments for TB. Germany reiterated that the Antimicrobial Resistance R&D Collaboration Hub will foster R&D to fight AMR including drug-resistant TB. It’s essential that other countries step up and new initiatives are created to tackle TB. The NIH also announced the institute’s new strategic plan for building on the current efforts by furthering the understanding of TB and developing and applying cutting-edge tools to fight the disease.

Leaders highlighted the need for new tools and funding for TB R&D at the UNHLM:

“We need increased investments, especially in science and research, and we need new medicines, new vaccines, and new diagnostics.” -Tedros Adhanom Ghebreyesus, Director General of the WHO

“We also need better tools to end the TB epidemic. Recently, we’ve witnessed encouraging research progress toward the development of improved TB vaccines and treatment regiments.” -Bill Gates, Co-Chair of BMGF

“Investing in research and development is critical if we are to develop new diagnostics, vaccines, and medicines. It is only with new tools that we can achieve dramatic reduction in the incidence of tuberculosis.” -Cyril Ramaphosa, President of South Africa


More News
27 Feb 2020
ERA4TB, or European Accelerator of Tuberculosis Regime, is a public-private initiative devoted to accelerate the development of new treatmen regimens for Tuberculosis. This project integrates more than thirty organizations from the European Union and the United States among which are the main...
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...